Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 173 clinical trials
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

This phase II trial studies how well a reduced intensity conditioning regimen after donor stem cell transplant works in treating patients with multiple myeloma that has come back (relapsed

tumor cells
monoclonal antibodies
daratumumab
mycophenolate mofetil
cyclophosphamide
  • 0 views
  • 25 Jan, 2021
Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

Ruxolitinib treatment prior to transplantation DAC+BF as myeloablative conditioning regimen CSA from day -3 and MMF from day +1 until day 28 ATG Neovii at dose of 7.5mg/KG for mismatch

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:

free conditioning regimen to be used for haplo-identical Hemtopoeitic stem cell transplant in acquired aplastic anemia patients

  • 4 views
  • 24 Jan, 2021
  • 2 locations
Allograft for Sickle Cell Disease and Thalassemia

>Transplant Conditioning Regimen - Immunosuppression without myeloablation: Patients will receive conditioning sufficient to allow donor lympho-hematopoietic engraftment without complete marrow

  • 28 views
  • 18 Feb, 2021
  • 1 location
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

addition of rituximab to the conditioning regimen, rates at 4 years for current progression-free survival (CPFS) and overall survival were 44% and 48%. The investigators hypothesize that

alemtuzumab
monoclonal protein
melphalan
lymphoid leukemia
monoclonal antibodies
  • 12 views
  • 08 Nov, 2020
  • 2 locations
Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

Background -DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent infections and possible death from infections or certain types of cancers, including blood cancers. A stem cell transplant is a life-saving treatment for this condition. In this study we are evaluating the …

  • 1 views
  • 05 Mar, 2021
  • 1 location
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

A randomized controlled study to assess the safety and efficacy and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.

  • 23 views
  • 05 Mar, 2021
  • 13 locations
Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation in patients with chronic granulomatous disease

gcsf
g-csf
stem cell transplantation
  • 0 views
  • 23 Jan, 2021
  • 1 location
RAPA-201 T Cell Therapy for Relapsed Refractory Multiple Myeloma

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter Phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.

  • 0 views
  • 02 Feb, 2021
  • 1 location
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab Busulfan and TBI With Post-Transplant Cyclophosphamide

Background CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want to see if they can lower the risks of using a mismatched donor. Objectives To see if it is safe to use a …

blood test
sirolimus
alemtuzumab
cyclophosphamide
busulfan
  • 1 views
  • 27 Jan, 2021
  • 1 location